代强,郑波

• 1:北京大学第一医院临床药理研究所

摘要(Abstract)：

<正>碳青霉烯类药物是治疗革兰阴性杆菌感染特别是肠杆菌科细菌的最强效-內酰胺类药物[1]。一旦碳青霉烯类药物耐药,临床治疗此类菌株感染将面临极大困难。目前,碳青霉烯类药物耐药的肠杆菌细菌(carbapenem-resistant enterobacteriaceae,CRE)已在很多国家出现和报道[2-5]。在美国地区传播的CRE耐药表型多为产肺炎克雷伯菌碳青霉烯酶(klebsiella pneumonia carbapenemase,KPC),

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 代强,郑波

参考文献(References)：

• [1]Rahal JJ.The role of carbapenems in initial therapy for serious Gram-negative infections[J].Crit Care,2008,12 Suppl 4:S5.
• [2]Yigit H,Queenan AM,Anderson GJ,et al.Novel carbapenemhydrolyzing beta-lactamase,KPC-1,from a carbapenemresistant strain of Klebsiella pneumoniae[J].Antimicrob Agents Chemother,2001,45(4):1151-1161.
• [3]Vatopoulos A.High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece-a review of the current evidence[J].Euro Surveill,2008,13(4):8023.
• [4]Oteo J,Delgado-Iribarren A,Vega D,et al.Emergence of imipenem resistance in clinical Escherichia coli during therapy[J].Int J Antimicrob Agents,2008,32(6):534-537.
• [5]Kaczmarek FM,Dib-Hajj F,Shang W,et al.High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1)beta-lactamase production,porin OmpK35/36 insertional inactivation,and down-regulation of the phosphate transport porin phoe[J].Antimicrob Agents Chemother,2006,50(10):3396-3406.
• [6]徐英春,肖永红,卓超,等.中国碳青霉烯类耐药肠杆菌科细菌的流行病学和防控策略[J].中国执业药师,2013,10(4):3-8.